Sun Pharma Completes Merger with Taro Pharmaceutical Subsidiary

Sun Pharmaceutical Industries Limited achieved a milestone today by finalizing the merger of Taro Pharmaceutical Industries Limited with its subsidiary. This move solidifies Sun Pharma’s position in the pharmaceutical industry, marking a new chapter in its growth trajectory and reputation.

About Taro Pharma

Headquartered in New York, Taro has operations in the US, Canada, Israel, and Japan. The company specializes in dermatology and produces a wide range of prescription and over-the-counter products. Taro’s manufacturing facilities are located in Canada (Brampton) and Israel (Haifa).

Merger Details 

Sun Pharma acquired all outstanding ordinary shares of Taro, making it a wholly-owned subsidiary. The acquisition involved purchasing 8,086,818 shares (21.52%) at a cost of Rs.2,891.76 crore. Taro shareholders were offered $43 per share in cash, representing a 48% premium. The total deal value amounted to $347.73 million.

Background and Negotiations 

Sun Pharma has been the majority shareholder of Taro since 2010. The merger process commenced when Sun Pharma proposed a non-binding offer to acquire all outstanding ordinary shares of Taro for $38 per share in May 2023. After negotiations, Taro’s special committee of independent directors agreed to a revised purchase price of $43 per share in December 2023. The merger certificate was issued by the Registrar of Companies in Israel on June 24, 2024.

Significance 

The merger allows Sun Pharma to leverage Taro’s strengths and capabilities, strengthening its overall competitiveness in the market. It signifies a consolidation of resources and expertise, enabling both companies to explore new opportunities for growth and innovation in the sector. With Taro now a private company wholly owned by Sun Pharma, the combined entity seems poised for a more successful future.

Conclusion The completion of the merger between Sun Pharma and its subsidiary Taro Pharmaceutical Industries marks an achievement for both companies. This move sets the stage for collaboration and growth, strengthening Sun Pharma’s position as a leader in the pharmaceutical industry in the country and globally as well.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.